DSGN — Q2 2026 Financial Report Analysis

Design Therapeutics is a clinical-stage drug developer, meaning it has no products on sale and no revenue. It spends investors' money on trials and hopes one drug works. Its lead drug, DT-216P2, is for Friedreich ataxia (FA), an inherited disease that gradually destroys coordination and damages the heart. FA happens because a genetic defect turns down a gene called frataxin (FXN). DT-216P2 is a small molecule from the company's "GeneTAC" platform, which is designed to turn that gene back up. The second quarter of 2026 had no revenue and a net loss of $20.2 million, up from $19.1 million a year earlier. Spending was close to flat. The quarter's real news was the first patient data in May, and the company's response: it is extending the trial to a 12-week cohort, with results due in Q1 2027.

The quarter in numbers

The company has no revenue, so operating margin (the share of sales left after running costs) doesn't mean anything here. For a company like this, the useful figures are spending and how long the cash lasts.

Where the R&D money went

The 10-Q splits R&D spending by program. Spending is moving toward the clinical programs:

The company says the R&D increase was "primarily due to an increase in FA clinical activities and higher indirect expenses." The new DM1 line is not entirely new spending. DM1 is myotonic dystrophy type 1, an inherited muscle-wasting disease. Its costs used to sit under "other direct" and now have their own line because the program has moved into clinical trials. That is mostly why "other direct" fell $3.0 million. G&A slipped slightly on lower stock-based compensation, meaning pay given as shares or options. Interest income fell 19%, from $2.5M to $2.0M. The cash pile is smaller than a year ago, and that interest is the only thing offsetting the company's losses.

What the headline numbers hide

• Cash burn is lower than the net loss. Net cash used in operations in the first half was $32.0 million, compared with a net loss of $37.8 million. The difference is mostly $7.8 million of stock-based compensation, which is a real cost to shareholders through dilution but uses no cash. In Q2 alone, cash and investments fell $15.4 million, from $222.8M to $207.4M, and no shares were sold that quarter.
• Runway: about 13 quarters at today's pace, probably fewer later. $207.4 million divided by roughly $16 million a quarter is about 13 quarters, which runs to around the third quarter of 2029. That matches the Q1 release's statement that cash would fund operations "into 2029." The Q2 release calls the runway "strong" but does not repeat the year. The 10-Q gives only the standard "more than the next 12 months." Neither number includes the higher cost of a registrational trial, the large late-stage trial used to seek approval, which the company plans to describe in Q4. The 10-Q also says plainly that current cash "will not be sufficient to fund any of our product candidates through regulatory approval."
• Dilution is the financing method. In Q1 2026 the company sold 2,006,550 new shares through its ATM program for $19.9 million net, roughly $9.90 per share. It sold none in Q2. Shares outstanding rose from 60.4 million at December 31 to 62.6 million at June 30. $53.9 million is still available under the ATM, and a $300 million shelf registration (pre-approval to sell securities when it chooses) is in place, so more shares can be sold at short notice.
• No one-offs distort the quarter. There are no impairments, no gains on sales and no milestone payments. A January 2026 lease amendment extended the company's Carlsbad lease to December 2029 at a lower rent. It increased the right-of-use asset by $1.3 million but did not affect results. This was a clean quarter. The loss is simply the cost of running three clinical programs.

The data that matters: RESTORE-FA

In May the company released four-week results from the Phase 1/2 RESTORE-FA trial (an early trial testing both safety and signs of benefit). Sixteen patients received weekly intravenous doses across four cohorts of 4 patients, from 0.1 to 1 mpk. At 1 mpk:

• Frataxin messenger RNA in blood (the gene's working copy, a direct sign the drug is reaching its target) rose 65% from baseline. Frataxin protein in blood rose 22–27%, measured two weeks after the last dose. Frataxin RNA in muscle rose 42%.
• Disability scores improved by a mean 6.4 points on the mFARS scale and 2.7 points on the Upright Stability Score. Patient-reported fatigue improved by more than 5 points, against the 3-point threshold usually treated as a meaningful change.
• There were no serious side effects and no dropouts. Three patients had mild-to-moderate, temporary rises in ALT, a liver enzyme. None had symptoms, and all were also taking omaveloxolone, the existing approved FA drug.

This matters because the company has tried this drug before. The original formulation, DT-216P1, had injection-site tolerability problems, and DT-216P2 is the reformulated version. The data reads well, but disability scores from four patients after four weeks are easily moved by chance and by patients' expectations. That is why the company has made blood frataxin protein change the trial's primary endpoint (the main measure the trial is judged on). It will enroll 10 patients in a longer 12-week cohort at 1 mpk and test a dose above 1 mpk.

Takeaway: Design's spending is steady and its cash should last into 2029, so the next 18 months depend on whether DT-216P2 works. The 12-week RESTORE-FA readout in Q1 2027 has to show that the frataxin increase and the early improvement in symptoms continue with longer dosing. If it does, the company will almost certainly need to raise money for a registrational trial. If it doesn't, the cash figure matters more than anything else on the balance sheet.

What to watch next

• Q4 2026: an update on registrational plans for DT-216P2. Watch for trial size and length, which together determine the cost. That decides whether the "into 2029" runway still holds.
• Q1 2027: RESTORE-FA results after 12 weeks of dosing, the first look at whether the four-week signal lasts.
• 2027: first patient data from the Phase 1 multiple-ascending-dose trial of DT-818 in DM1 (dosing started this summer). Also Phase 2 biomarker data for DT-168 eye drops in Fuchs endothelial corneal dystrophy (FECD), an inherited eye disease that clouds the cornea. That readout slipped from earlier guidance to 2027 because of a delay in supplying the eye-dropper packaging.
• Spending trend: quarterly operating cash burn has been about $16 million. Expect it to rise as the FA program moves toward a registrational trial and DM1 trial costs grow. Also watch for more ATM sales: with $53.9 million still available under the program, further dilution is likely.
• Status change: Design stops being an "emerging growth company" after December 31, 2026. That status gives newly listed companies lighter reporting rules, so some compliance costs, such as an outside audit of internal controls, are likely to go up in 2027.

The full Q3 2026 10-Q has not been filed yet. Going by last year's timing, it should arrive in early November.